Table 2. Baseline characteristics of included studies.
|
ECOG PS |
BCLC stage |
Child-Pugh score |
HCC aetiology |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| References | Treatment arms | N | 0 | 1 | 2 | A | B | C | D | A | B | C | HBV | HCV | Alcoholic |
| Llovet et al (2008b) | Sorafenib | 290 | 54% | 38% | 8% | 0% | 18% | 82% | 0% | 95% | 5% | 0% | 19% | 29% | 26% |
| Placebo | 303 | 54% | 39% | 7% | 0% | 17% | 83% | 0% | 98% | 2% | 0% | 18% | 27% | 26% | |
| Cheng et al (2009) | Sorafenib | 150 | 25% | 69% | 5% | N/A | N/A | 95% | N/A | 97% | 3% | 0% | 71% | 11% | N/A |
| Placebo | 76 | 28% | 67% | 5% | N/A | N/A | 96% | N/A | 97% | 3% | 0% | 78% | 4% | N/A | |
| Llovet et al (2013) | Brivanib | 263 | 57% | 39% | 4% | 3% | 9% | 87% | 1% | 92% | 7% | 1% | 39% | 28% | 23% |
| Placebo | 132 | 61% | 35% | 4% | 1% | 14% | 85% | 0% | 91% | 9% | 0% | 34% | 27% | 27% | |
| Johnson et al (2013) | Brivanib | 577 | 64% | 36% | 0% | 6% | 17% | 77% | 0% | 92% | 8% | 0% | 44% | 20% | 18% |
| Sorafenib | 578 | 61% | 39% | 0% | 5% | 17% | 78% | 0% | 92% | 8% | 0% | 45% | 21% | 14% | |
| Cheng et al (2013) | Sunitinib | 530 | 53% | 47% | 0% | 0% | 13% | 87% | 0% | 100% | 0% | 0% | 55% | 21% | 17% |
| Sorafenib | 544 | 53% | 47% | 0% | 0% | 16% | 84% | 0% | 100% | 0% | 0% | 53% | 22% | 15% | |
| Zhu et al (2014) | Everolimus | 362 | 59% | 36% | 5% | 0% | 14% | 86% | 0% | 98% | 2% | 0% | 25% | 26% | 18% |
| Placebo | 184 | 57% | 40% | 3% | 0% | 14% | 86% | 0% | 99% | 1% | 0% | 28% | 23% | 25% | |
| Cainap et al (2015) | Linifanib | 514 | 63% | 37% | 0% | 0% | 16% | 84% | 0% | 94% | 6% | 0% | 54% | 25% | 13% |
| Sorafenib | 521 | 66% | 34% | 0% | 0% | 20% | 80% | 0% | 95% | 5% | 0% | 53% | 25% | 12% | |
| Zhu et al (2015b) | Sorafenib+Erlotinib | 362 | 61% | 39% | 0% | 0% | 17% | 83% | 0% | 100% | 0% | 0% | 34% | 30% | N/A |
| Sorafenib+Placebo | 358 | 60% | 40% | 0% | 0% | 13% | 87% | 0% | 100% | 0% | 0% | 37% | 24% | N/A | |
| Zhu et al (2015a) | Ramucirumab | 283 | 56% | 44% | 0% | 0% | 12% | 88% | 0% | 56% | 44% | 0% | 35% | 27% | N/A |
| Placebo | 282 | 54% | 46% | 0% | 0% | 12% | 88% | 0% | 54% | 46% | 0% | 36% | 27% | N/A | |
Abbreviations: BCLC=Barcelona Clinic Liver Cancer; ECOG PS=Eastern Cooperative Oncology Group performance status; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; HCV=hepatitis C virus; N=number; N/A=not available.